Zhizhuxiang Capsules Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is released as a multi-route active pharmaceutical ingredient whose grade designation is tied to the intended dosage form rather than to a single pharmacopoeial monograph identity. The model code is the manufacturer’s veterinary-grade identifier; no international nonproprietary name or compendial monograph currently assigns the trade name to a single chemical entity, and therefore the certificate of analysis remains the controlling document for batch-specific assay, related substances, residual solvent, and elemental impurity profiles. Material intended for solid oral dosage forms is released under non-sterile requirements consistent with Ph. Eur. 5.1.4, while injectable and solution routes require additional endotoxin, sterility, and sub-visible particulate controls consistent with Ph. Eur. 2.6.14, Ph. Eur. 5.1.1, and USP ⟨788⟩. Specification layers include identity by infrared or chromatographic retention, assay by high-performance liquid chromatography, related substances by gradient HPLC, residual solvents by headspace gas chromatography, elemental impurities by inductively coupled plasma-mass spectrometry, water content by Karl Fischer titration, and particle size distribution by laser diffraction. Each dosage form imposes a distinct release profile: tablet and capsule grades emphasize flow, compressibility, and dissolution; premix grades emphasize dilution homogeneity and segregation resistance; injection grades emphasize endotoxin burden, particulate load, osmotic compatibility, and sterility.

What separates injectable-grade Zhizhuxiang API from oral premix-grade material?

Injectable-grade material cannot be generated by repackaging feed-grade or oral-grade powder. The bacterial endotoxin acceptance criterion is derived from the maximum bolus dose and route of administration under USP ⟨85⟩, using the relationship E = K/M, where K is 5 EU/kg for intravenous administration and M is the maximum dose in mg per kg of body weight per hour. For an illustrative intravenous dose of 10 mg/kg/h, the resulting API endotoxin limit is ≤0.5 EU/mg; lower doses or intrathecal routes can drive the limit below 0.1 EU/mg. Injectable-grade material must also pass sterility testing by direct inoculation or membrane filtration according to Ph. Eur. 5.1.1, and sub-visible particulate matter is controlled by light obscuration with acceptance values for containers under USP ⟨788⟩ of ≥10 µm: ≤6000 per container and ≥25 µm: ≤600 per container. Oral premix-grade material, by contrast, is non-sterile and is released only when total aerobic microbial count does not exceed 100 CFU/g, total combined yeasts and moulds does not exceed 10 CFU/g, and bile-tolerant gram-negative bacteria are absent in 1 g under Ph. Eur. 5.1.4. The route-specific difference also changes processing: injectable-grade API requires depyrogenated containers, dedicated air handling, and terminal filtration through 0.22 µm membranes, whereas oral premix-grade material is dispersed into feed carriers under standard dry blending conditions.

For tablet and capsule processing, the API is dry-blended in a bin blender with an intensifier bar at 10–15 rpm until blend uniformity meets Ph. Eur. 2.9.40 acceptance values. Wet granulation in a high-shear mixer requires purified water addition until impeller torque reaches 40–60% of motor load; granulates are dried in a fluid-bed dryer with inlet air 55–65°C to loss-on-drying ≤2.0%. Milling through a conical mill with 0.8 mm screen provides granules with D50 200–400 µm. Tablets are compressed on a rotary press with precompression force 5–10 kN and main compression 20–35 kN; hardness target is 70–120 N depending on dissolution response. Capsule filling with a dosator or tamping-pin machine requires tapped density 0.45–0.70 g/mL and Carr index ≤25 for consistent fill weight. For powders intended for direct use, the particle size distribution is measured by laser diffraction under ISO 13320; a D90 below 250 µm is normally targeted when the product is combined into a 1:100 or higher dilution premix to reduce segregation. These processing windows are representative for medium-density botanical or synthetic veterinary APIs; published data for the specific Zhizhuxiang trade-name configuration are limited, and development-scale confirmation against the manufacturer’s CoA is required before transfer to production equipment.

Solubility, pH, and solution stability place measurable constraints on formulation

Solution and injection use requires characterization of aqueous solubility across pH 2.0–8.0 at 20–25°C. Potentiometric pH is measured according to Ph. Eur. 2.2.3, and osmolality is measured according to Ph. Eur. 2.2.35. For multidose or single-dose preparations, the API is dissolved initially in a portion of water for injection with agitation at 200–500 rpm; pH is corrected with 0.1 M hydrochloric acid or 0.1 M sodium hydroxide to a target range of pH 4.5–6.5 unless forced degradation data justify an alternative. If terminal steam sterilization at 121°C for 15 min is used, the cycle must be validated by sterility testing under Ph. Eur. 5.1.1 and supported by assay and related substance data showing no degradation outside the release specification. When terminal sterilization is not feasible because of heat lability, aseptic filtration through a 0.22 µm polyethersulfone filter is performed into depyrogenated vials, followed by sterility and sub-visible particulate testing under Ph. Eur. 2.9.19 and USP ⟨788⟩. Multidose solutions containing no preservative are limited by the absence of antimicrobial efficacy; where preservative is present, the formulation must meet the acceptance criteria of Ph. Eur. 5.1.3 for antimicrobial preservation. The difference from solid oral forms is that solution stability is controlled by first-order degradation kinetics and pH-dependent hydrolysis rather than by moisture sorption and tablet hardness.

Residual solvent and elemental impurity control points

Residual solvent testing follows headspace gas chromatography with flame ionization detection or mass spectrometry, and limits are selected according to ICH Q3C(R8) and the veterinary Guideline VICH GL18(R2). Class 1 solvents are controlled at parts-per-million levels; Class 2 solvents are controlled at the permitted daily exposure converted to concentration limits by the product’s maximum daily dose. Elemental impurity control is aligned with ICH Q3D and the veterinary equivalent VICH GL30, with route-specific limits for As, Cd, Hg, and Pb applied by inductively coupled plasma-mass spectrometry. The following representative Class 1 and Class 2 limits are compendial default values and do not replace product-specific CoA limits.

Differences from other products are most visible in the grade comparison matrix. A technical-grade material may have assay, impurity, solvent, and residue profiles that are not suitable for therapeutic administration; a veterinary oral/premix grade must meet non-sterile microbial and solvent limits but is not required to be sterile; a veterinary injectable grade must meet endotoxin, sterility, particulate, and osmolality controls. Human-grade API is produced under ICH Q7 and often under dedicated line changeover controls, but it may lack food-producing species residue depletion and withdrawal period documentation required under Regulation (EU) No 37/2010 and Regulation (EU) 2019/6. The Zhizhuxiang veterinary-grade designation is therefore not simply a purity label; it indicates that the batch is accompanied by route-specific documentation, stability data, and contamination controls suitable for veterinary pharmaceutical formulation.

When formulation into premix approaches a 1:100 dilution ratio, segregation risk dominates process capability

Premix and granule dilution requires assessment of particle size mismatch, density difference, and electrostatic charge. If the API has D50 50–150 µm and the feed carrier has D50 300–800 µm, dry blending in a ribbon blender at 20–40 rpm can achieve homogeneity but the mixture is sensitive to segregation during discharge and transport. Sampling under ISO 2859-1 or an equivalent acceptance sampling plan is used to verify that active content remains within ±10% of the labeled claim across 10 sampled points. Segregation is reduced by matching carrier particle size distribution, adding binder such as 2–5% povidone or starch paste during wet granulation, and controlling residual moisture to ≤5.0%. For powder and premix operations without granulation, the API should be pre-blended with a small portion of carrier at 1:3 before addition to the full batch; this staged dilution is evaluated by blend uniformity testing under Ph. Eur. 2.9.40. Equipment-specific failure modes include dead zones at the base of vertical mixers, and electrostatic coating of the conveyor if relative humidity falls below 30%; when ambient RH is below 30%, grounding of the blender and controlled humidification to 40–45% RH reduce charge accumulation. The difference from tablet and capsule formulations is that premix does not benefit from unit-dose metal detection or individual hardness testing, so the entire batch must remain uniform under practical field handling conditions.

Storage stability is controlled under long-term conditions of 25°C/60% RH and accelerated conditions of 40°C/75% RH according to VICH GL3 and ICH Q1A(R2) principles. Packaging must provide a moisture barrier; aluminum foil pouches, PVDC-coated blisters, or HDPE drums with desiccant are selected based on moisture vapor transmission rate. At relative humidity above 60%, powders and granules should be pre-dried before tableting or capsule filling to avoid picking, sticking, and poor flow. The product should not be mixed with amine-based additives when solution stability data show risk of Schiff-base formation or premature degradation; compatibility studies using binary mixtures stored at 40°C/75% RH for 4 weeks are required before any new excipient is introduced. For injections and solutions, the API solution should be protected from light when photodegradation data show a measurable increase in related substances after 24 h under ICH Q1B light conditions. The operational boundary is therefore defined not by a single storage temperature but by the dosage form, packaging, and the validated retest period in the manufacturer’s stability summary.